Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...

Soleno Therapeutics today announced that the US FDA has approved VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and children four years of age and ...

Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025. “The approval of VYKAT XR is a significant milestone for Soleno and, most importantly, for the PWS community who have ...

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic disorder that causes excessive appetite and obesity. Vykat XR (diazoxide ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.